◎ Sugi Atlas

Atlas / Drug / Sildenafil

Sildenafil

drug
On this page

Also known as HIP-0908HIP0908SildenafiloUK-92480SID26748898SID50085897SID29215463SID174007057SILDENAFIL CITRATE

Summary

Sildenafil (CHEMBL192) is an approved small-molecule vasodilator agent (ATC G04BE03) targeting SLCO1B3, SLCO2B1, and PDE5A; indicated across 60 conditions including erectile dysfunction and idiopathic pulmonary fibrosis.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: G04BE03
  • Targets: 5 (SLCO1B3, SLCO2B1, PDE5A…)
  • Indications: 60 conditions
  • Clinical trials: 332
  • Chemistry: 474.6 Da · C22H30N6O4S

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL192
NameSildenafil
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID135398744
ChEBICHEBI:9139
ATCG04BE03
Molecular formulaC22H30N6O4S
Molecular weight474.6
InChIKeyBNRNXUUZRGQAQC-UHFFFAOYSA-N

SMILES: CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C

IUPAC name: 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,5-d]pyrimidin-7-one

ChEBI definition: A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.

Pharmacological roles (ChEBI): vasodilator agent, EC 3.1.4.35 (3’,5’-cyclic-GMP phosphodiesterase) inhibitor.

Also known as: HIP-0908, HIP0908, Sildenafil, Sildenafilo, UK-92480, sildenafil, SID26748898, SID50085897, SID29215463, SILDENAFIL, SID174007057, SILDENAFIL CITRATE

Parent form; salt/anhydrous children: CHEMBL1737, CHEMBL5276310

Patent coverage: 11,139 distinct patent families (41,819 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 40,204 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
SLCO1B3OATP1B3Inhibition6.10%Q9NPD5
SLCO2B1OATP2B1Inhibition0%O94956
PDE5Aphosphodiesterase 5AInhibition90%O76074
PDE6Cphosphodiesterase 6CInhibition7.410.2%P51160
ABCC5ABCC5Inhibition5.920%O15440

Broader ChEMBL bioactivity targets: 42 (assay-derived). Sample: ATP-binding cassette sub-family C member 4, cGMP-specific 3’,5’-cyclic phosphodiesterase, Voltage-dependent L-type calcium channel subunit alpha-1C, Beta-lactamase, ATP-binding cassette sub-family C member 5, Phosphodiesterase 4, Phosphodiesterase 3, Phosphodiesterase 4, Phosphodiesterase 1, Phosphodiesterase 6.

Bioactivity

ChEMBL activities: 149 potent at pChembl ≥ 5 of 170 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
O547359.52IC500.3nMCHEMBL_ACT_536081
PDE6D9.3IC500.5nMCHEMBL_ACT_12680603
O777469IC501nMCHEMBL_ACT_1247680
PDE5A9IC501nMCHEMBL_ACT_19236561
PDE5A8.85IC501.4nMCHEMBL_ACT_24873452
PDE5A8.8IC501.6nMCHEMBL_ACT_1243003
PDE5A8.8IC501.6nMCHEMBL_ACT_15070250
PDE5A8.8Ki1.6nMCHEMBL_ACT_18771536
PDE5A8.8IC501.6nMCHEMBL_ACT_477010
PDE5A8.8IC501.6nMCHEMBL_ACT_584306
PDE5A8.8IC501.6nMCHEMBL_ACT_726578
PDE5A8.8IC501.6nMCHEMBL_ACT_885958
PDE5A8.8IC501.6nMCHEMBL_ACT_925443
PDE5A8.75IC501.78nMCHEMBL_ACT_924690
O547358.74Ki1.8nMCHEMBL_ACT_1400247
PDE5A8.73Ki1.87nMCHEMBL_ACT_268223
PDE5A8.73Ki1.87nMCHEMBL_ACT_322721
PDE5A8.72Ki1.91nMCHEMBL_ACT_1269964
PDE5A8.72Ki1.91nMCHEMBL_ACT_280637
O547358.7IC502nMCHEMBL_ACT_19117131
PDE5A8.66IC502.2nMCHEMBL_ACT_12680607
PDE5A8.66IC502.2nMCHEMBL_ACT_18527310
PDE5A8.66IC502.2nMCHEMBL_ACT_19400628
PDE5A8.66IC502.2nMCHEMBL_ACT_19400631
PDE5A8.66IC502.2nMCHEMBL_ACT_19400634
PDE5A8.52IC503nMCHEMBL_ACT_1521901
PDE5A8.52IC503nMCHEMBL_ACT_23143636
PDE5A8.52IC503nMCHEMBL_ACT_23143711
PDE5A8.52IC503nMCHEMBL_ACT_837349
PDE5A8.46IC503.5nMCHEMBL_ACT_1520494

Target pathways

Aggregated over 5 target gene(s): SLCO1B3, SLCO2B1, PDE5A, PDE6C, ABCC5.

Top Reactome pathways

28 total, by targets touching each:

PathwayTargetsGenes
Transport of small molecules3ABCC5, SLCO1B3, SLCO2B1
Metabolism2ABCC5, SLCO1B3
Heme degradation2SLCO1B3, SLCO2B1
Transport of vitamins, nucleosides, and related molecules2SLCO1B3, SLCO2B1
SLC-mediated transmembrane transport2SLCO1B3, SLCO2B1
Organic anion transport by SLCO transporters2SLCO1B3, SLCO2B1
Drug ADME2ABCC5, SLCO1B3
Atorvastatin ADME2SLCO1B3, SLCO2B1
Recycling of bile acids and salts1SLCO1B3
Glycosaminoglycan metabolism1ABCC5
Disease1SLCO1B3
Metabolism of porphyrins1SLCO1B3
Bile acid and bile salt metabolism1SLCO1B3
Hyaluronan metabolism1ABCC5
R-HSA-21428501ABCC5
ABC-family protein mediated transport1ABCC5
cGMP effects1PDE5A
Smooth Muscle Contraction1PDE5A
Metabolism of lipids1SLCO1B3
Defective SLCO1B3 causes hyperbilirubinemia, Rotor type (HBLRR)1SLCO1B3
SLC transporter disorders1SLCO1B3
Disorders of transmembrane transporters1SLCO1B3
Metabolism of carbohydrates and carbohydrate derivatives1ABCC5
Metabolism of steroids1SLCO1B3
RHOBTB1 GTPase cycle1PDE5A
Azathioprine ADME1ABCC5
Aspirin ADME1SLCO2B1
Paracetamol ADME1ABCC5

Dominant GO biological processes

GO termTargets
xenobiotic metabolic process3
transmembrane transport3
monoatomic ion transport2
obsolete organic anion transport2
bile acid and bile salt transport2
heme catabolic process2
sodium-independent organic anion transport2
transport across blood-brain barrier2
signal transduction2
negative regulation of cAMP/PKA signal transduction2
lipid transport1
prostaglandin transport1
cGMP catabolic process1
visual perception1
phototransduction, visible light1

Indications & clinical

Indications

60 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
erectile dysfunction4MONDO:0005362EFO:0004234
idiopathic pulmonary fibrosis3MONDO:0800504EFO:0000768
pulmonary arterial hypertension3MONDO:0015924EFO:0001361
heart failure3MONDO:0005252EFO:0003144
hypertensive disorder3MONDO:0005044EFO:0000537
peripheral arterial disease3MONDO:0005386EFO:0004265
lung disorder3MONDO:0005275EFO:0003818
systemic sclerosis3MONDO:0005100EFO:0000717
congestive heart failure3MONDO:0005009EFO:0000373
diabetes mellitus3MONDO:0005015EFO:0000400
coronary vasospasm3MONDO:0005356EFO:0004225
persistent fetal circulation syndrome3MONDO:0022430EFO:1001103
Eisenmenger syndrome3MONDO:0019944EFO:0009200
pulmonary hypertension3MONDO:0005149MONDO:0005149
glaucoma3MONDO:0005041MONDO:0005041
beta thalassemia3MONDO:0019402Orphanet:848
rectal cancer3MONDO:0006519EFO:1000657
physiological sexual disorder2MONDO:0002134EFO:0004714
benign prostatic hyperplasia2MONDO:0010811EFO:0000284
fetal growth restriction2MONDO:0005030EFO:0000495
infertility disorder2MONDO:0005047EFO:0000545
Raynaud disease2MONDO:0008364EFO:1001145
preeclampsia2MONDO:0005081EFO:0000668
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
brain disorder2MONDO:0005560HP:0001298
priapism2MONDO:0004745HP:0200023
brain injury2MONDO:0043510MONDO:0043510
scleroderma2MONDO:0019340EFO:1001993
hypoplastic left heart syndrome2MONDO:0004933MONDO:0004933
Parkinson disease2MONDO:0005180MONDO:0005180
cystic fibrosis2MONDO:0009061MONDO:0009061
Duchenne muscular dystrophy2MONDO:0010679MONDO:0010311
bronchopulmonary dysplasia2MONDO:0019091MONDO:0019091
premature ejaculation2MONDO:0001780EFO:0803321
heart disorder1MONDO:0005267EFO:0003777
acute kidney injury1MONDO:0002492HP:0001919
cirrhosis of liver1MONDO:0005155EFO:0001422
myelodysplastic syndrome1MONDO:0018881EFO:0000198
hepatitis C virus infection1MONDO:0005231EFO:0003047
pulmonary embolism1MONDO:0005279EFO:0003827
female infertility1MONDO:0021124EFO:0008560
mycobacterial infectious disease1MONDO:0020590EFO:0009429
lymphangioma1MONDO:0002013MONDO:0002013
coronary artery disorder1MONDO:0005010EFO:0001645
severe acute respiratory syndrome1MONDO:0005091MONDO:0100096
perinatal asphyxia1MONDO:0006663EFO:1000824
sickle cell disease1MONDO:0011382MONDO:0011382
skin disorder0MONDO:0005093EFO:0000701
pulmonary edema0MONDO:0006932EFO:1001134
patent foramen ovale0MONDO:0020439HP:0001655
migraine with aura0MONDO:0005475MONDO:0005475

9 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 332.

Phase distribution

PhaseTrials
PHASE487
PHASE260
Not specified49
PHASE348
PHASE146
PHASE2/PHASE320
PHASE1/PHASE212
EARLY_PHASE110

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02682147PHASE4ACTIVE_NOT_RECRUITINGFunctional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema
NCT06649539PHASE4RECRUITINGDelayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie’s Disease
NCT06875258PHASE4RECRUITINGPEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)
NCT00133679PHASE4TERMINATEDChronic Sildenafil for Severe Diaphragmatic Hernia
NCT00145483PHASE4COMPLETEDSildenafil For Meniere’s Disease
NCT00147628PHASE4COMPLETEDAssessment Of Sildenafil On Erectile Function And Intercourse Satisfaction And To Validate A New Subject Questionnaire
NCT00150358PHASE4COMPLETEDTo Yield Further Information On The Efficacy And Safety Of Viagra Among Subjects With Arterial Hypertension .
NCT00151463PHASE4COMPLETEDQEQ Treatment Responsiveness Evaluation Study
NCT00159900PHASE4COMPLETEDQuality of Erection Study
NCT00194909PHASE4COMPLETEDAn Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus)
NCT00245258PHASE4COMPLETEDStudy to Evaluate Viagra’s Ability to Provide a Better Sexual Experience Through Quality Erections and Satisfaction
NCT00245596PHASE4COMPLETEDEvaluation of the Index of Sexual Life Questionnaire
NCT00249730PHASE4COMPLETEDTitration Study to Evaluate Efficacy and Satisfaction of Viagra in Men With Erectile Function.
NCT00251784PHASE4COMPLETEDHealthy Volunteer Study of Sildenafil Effects Upon Vision
NCT00313898PHASE4UNKNOWNEffect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
NCT00323297PHASE4COMPLETEDAssess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
NCT00350441PHASE4UNKNOWNDoes Sildenafil Protect Against Pulmonary Related Complications Following Cardiopulmonary Bypass?
NCT00375297PHASE4COMPLETEDStudy of Sildenafil for Treatment of SSRI-Antidepressant Sexual Dysfunction in Women
NCT00430716PHASE4TERMINATEDTo Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.
NCT00433329PHASE4COMPLETEDCombination Therapy in Pulmonary Arterial Hypertension
NCT00455715PHASE4COMPLETEDA Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia
NCT00461565PHASE4COMPLETEDFDA Phase IV - Commitment - Retinal Function Study
NCT00468650PHASE4COMPLETEDA Multicenter, Open Label, To Evaluate The Efficacy And Satisfaction Of Patrex® In Men With Erectile Dysfunction.
NCT00479908PHASE4COMPLETEDBlood Pressure Interaction Between Sildenafil and Sublingual Glyceryl Trinitrate (GTN) in Men With Angina
NCT00483626PHASE4UNKNOWNHemodynamic Response After Six Months of Sildenafil
NCT00491803PHASE4COMPLETEDSildenafil Effects on Pulmonary Haemodynamics and Gas Exchange in Chronic Obstructive Pulmonary Disease (COPD)
NCT00498680PHASE4UNKNOWNSafety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i’s vs. Single Maximal Dose PDE5i
NCT00547092PHASE4COMPLETEDStudy For Which Treatment, Tadalafil or Sildenafil, is Preferred For Problems Getting or Maintaining an Erection
NCT00547352PHASE4COMPLETEDStudy to Determine a Preference Between Sildenafil or Tadalafil Treatment for Problems Getting an Erection
NCT00598585PHASE4COMPLETEDUse of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS
NCT00617305PHASE4COMPLETEDStudy of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
NCT00625079PHASE4WITHDRAWNPulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
NCT00627965PHASE4COMPLETEDRandomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness
NCT00644631PHASE4COMPLETEDA Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Sildenafil Citrate
NCT00644956PHASE4COMPLETEDA Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Sildenafil And Tadalafil
NCT00645268PHASE4COMPLETEDA Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes
NCT00648596PHASE4COMPLETEDA Study to Evaluate Self-esteem and Relationships in Males With Erectile Dysfuntion
NCT00654017PHASE4COMPLETEDA Study Evaluating the Efficacy and Safety of Sildenafil in Patients With Erectile Dysfunction Receiving Hemodialysis
NCT00654082PHASE4COMPLETEDA Study Evaluating the Efficacy and Safety of Sildenafil in Men With Traumatic Spinal Cord Injury and Erectile Dysfunction
NCT00655590PHASE4COMPLETEDAssess the Effect of Daily Treatment of Vardenafil 20mg or Sildenafil 100mg and Placebo on Sperm Function

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

328 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
DipyridamoleChEMBL + PubChemPhase 4 (approved)ABCC5, PDE5A, PDE6C, SLCO2B1
CelecoxibChEMBL + PubChemPhase 4 (approved)PDE5A, SLCO1B3, SLCO2B1
RIFAMPINChEMBL + PubChemPhase 4 (approved)ABCC5, SLCO1B3, SLCO2B1
ATAZANAVIRChEMBL + PubChemPhase 4 (approved)SLCO1B3, SLCO2B1
AtorvastatinChEMBL + PubChemPhase 4 (approved)SLCO1B3, SLCO2B1
CLARITHROMYCINChEMBL + PubChemPhase 4 (approved)SLCO1B3, SLCO2B1
CYCLOSPORINEChEMBL + PubChemPhase 4 (approved)SLCO1B3, SLCO2B1
DIGOXINChEMBL + PubChemPhase 4 (approved)SLCO1B3, SLCO2B1
DOXORUBICINChEMBL + PubChemPhase 4 (approved)SLCO1B3, SLCO2B1
ERLOTINIBChEMBL + PubChemPhase 4 (approved)SLCO1B3, SLCO2B1
ETOPOSIDEChEMBL + PubChemPhase 4 (approved)SLCO1B3, SLCO2B1
GEMFIBROZILChEMBL + PubChemPhase 4 (approved)SLCO1B3, SLCO2B1
INDOMETHACINChEMBL + PubChemPhase 4 (approved)SLCO1B3, SLCO2B1
MITOXANTRONEChEMBL + PubChemPhase 4 (approved)SLCO1B3, SLCO2B1
OLMESARTAN MEDOXOMILChEMBL + PubChemPhase 4 (approved)SLCO1B3, SLCO2B1
PACLITAXELChEMBL + PubChemPhase 4 (approved)SLCO1B3, SLCO2B1
PRAVASTATINChEMBL + PubChemPhase 4 (approved)SLCO1B3, SLCO2B1
RIFAMYCINChEMBL + PubChemPhase 4 (approved)SLCO1B3, SLCO2B1
RITONAVIRChEMBL + PubChemPhase 4 (approved)SLCO1B3, SLCO2B1
TADALAFILChEMBL + PubChemPhase 4 (approved)PDE5A, PDE6C
TANNIC ACIDChEMBL + PubChemPhase 4 (approved)PDE5A, SLCO1B3
TELMISARTANChEMBL + PubChemPhase 4 (approved)SLCO1B3, SLCO2B1
VARDENAFILChEMBL + PubChemPhase 4 (approved)PDE5A, PDE6C
VINBLASTINEChEMBL + PubChemPhase 4 (approved)SLCO1B3, SLCO2B1
VINCRISTINEChEMBL + PubChemPhase 4 (approved)SLCO1B3, SLCO2B1
ELTROMBOPAGChEMBLPhase 4 (approved)SLCO1B3, SLCO2B1
SULFASALAZINEChEMBLPhase 4 (approved)SLCO1B3, SLCO2B1
SILYBIN AChEMBLPhase 3SLCO1B3, SLCO2B1
GENISTEINChEMBL + PubChemPhase 2 (approved)SLCO1B3, SLCO2B1
GLYCYRRHIZINChEMBL + PubChemPhase 2 (approved)SLCO1B3, SLCO2B1
SILICRISTINChEMBLPhase 2SLCO1B3, SLCO2B1
ZAPRINASTChEMBLPhase 2PDE5A, PDE6C
AcyclovirPubChemApprovedSLCO1B3, SLCO2B1
AllopurinolPubChemApprovedSLCO1B3, SLCO2B1
AmantadinePubChemApprovedSLCO1B3, SLCO2B1
aminohippuric acidPubChemApprovedSLCO1B3, SLCO2B1
AmitriptylinePubChemApprovedSLCO1B3, SLCO2B1
AtenololPubChemApprovedSLCO1B3, SLCO2B1
BuspironePubChemApprovedSLCO1B3, SLCO2B1
CaffeinePubChemApprovedSLCO1B3, SLCO2B1
CandesartanPubChemApprovedSLCO1B3, SLCO2B1
CarbamazepinePubChemApprovedSLCO1B3, SLCO2B1
CetirizinePubChemApprovedSLCO1B3, SLCO2B1
ChloroquinePubChemApprovedSLCO1B3, SLCO2B1
Cholic AcidPubChemApprovedSLCO1B3, SLCO2B1
DexamethasonePubChemApprovedSLCO1B3, SLCO2B1
dinoprostonePubChemApprovedABCC5, SLCO2B1
ErythromycinPubChemApprovedSLCO1B3, SLCO2B1
EzetimibePubChemApprovedSLCO1B3, SLCO2B1
MetforminPubChemApprovedSLCO1B3, SLCO2B1
MethotrexatePubChemApprovedSLCO1B3, SLCO2B1
PhenytoinPubChemApprovedSLCO1B3, SLCO2B1
ProbenecidPubChemApprovedABCC5, SLCO2B1
theophyllinePubChemApprovedSLCO1B3, SLCO2B1
ValacyclovirPubChemApprovedSLCO1B3, SLCO2B1
VerapamilPubChemApprovedSLCO1B3, SLCO2B1
CANDESARTAN CILEXETILChEMBL + PubChemPhase 4 (approved)SLCO1B3
CHLORAMBUCILChEMBL + PubChemPhase 4 (approved)SLCO1B3
HYDROXYZINE PAMOATEChEMBL + PubChemPhase 4 (approved)SLCO1B3
AVANAFILChEMBLPhase 4 (approved)PDE5A

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot